New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 25, 2013
18:02 EDTMNOVFDA grants fast track designation for MedicNova's MN-166
MediciNova and the Jasdaq Market of the Osaka Securities Exchange (Code Number: 4875), announced that it has received Fast Track designation from the U.S. FDA for MN-166 (ibudilast) for the treatment of methamphetamine dependence. Fast Track is a process designed to facilitate the development and expedite the review of drugs that are intended to treat serious diseases and have the potential to fill an unmet medical need. An important feature of the FDA's Fast Track program is that it emphasizes early and frequent communication between the FDA and the sponsor throughout the entire drug development and review process to improve the efficiency of product development. Accordingly, Fast Track status can potentially lead to a shortened timeline to ultimate drug approval.
News For MNOV From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 21, 2015
13:47 EDTMNOVMediciNova reports positive interim data from clinical trial of MN-166 in ALS
Subscribe for More Information
April 16, 2015
09:18 EDTMNOVOn The Fly: Pre-market Movers
Subscribe for More Information
08:12 EDTMNOVMediciNova MN-001 granted fast track designation by FDA
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use